The National Institute for Health and Clinical Excellence (NICE) has been invited to carry out an appraisal of nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer. We have recently invited stakeholders to respond to a written consultation on the draft scope which closed on 8 August 2019. The company developing nivolumab, Bristol-Myers Squibb, has advised NICE that they are unable to provide an evidence submission within the scheduled timelines.
In light of this information NICE will be suspending this appraisal. If you have any comments or concerns please contact the Project Manager for this appraisal Kate Moore on TACommD@nice.org.uk